Nav: Home

Skin cancer teams up with Sonic the Hedgehog

March 08, 2016

Basal cell carcinoma (also known as basalioma or basal cell cancer -- BCC) is the most common, and the 5th expensive cancer type to cure, making about 90% of malignant skin tumors. Among risk factors there are genetic malfunctions, appearance of freckles, x-rays and radiation, burns or use of immunosuppressive medication (for organ transplantation, for instance).

'The work led by Sergey Nikolaev, University of Geneva, resulted in a finding that more than 80% of BCC cases contain gene mutations leading to tumor formation of other types, that were not associated with BCC initially. This discovery proves the existence of mechanisms helping BCC to resist anticancer therapy, which opens new range of opportunities for further clinical trials,' explains Vladimir Seplyarskiy, coauthor of the paper and junior researcher at the Bioengineering and Bioinformatics Department, Moscow State University.

Supersonic hedgehog & Co

Among genes and corresponding proteins where mutative malfunctions provoke cancer in 'the basal cell carcinoma inquiry' appear the elements of a Sonic hedgehog (Hh) signaling pathway. Hh manages task distribution among cells during the embryogenesis and further 'self-determination', as well as forming of organs' left-side and right-side orientation.

Under normal conditions the Sonic hedgehog signaling pathway is started by an eponymous signaling protein. Found first in drosophila, the Sonic hedgehog gene, which's absence made flies' embryos look like thorny balls, was actually named after Supersonic The Hedgehog, a character of comics and videogames.

85% of basalioma cover gene of the Sonic hedgehog signaling pathway, which leads to it's activation without a help of the 'regulating hedgehog'.

There belong PTCH1 receptors and SMO protein immersed in the cell membrane, which passes the hedgehogs protein's instruction to start protein synthesis to Gli transcription factor. Together with that, among 'the accused' in more than a half of tumor cells a 'broken' version of TP53 gene can be found, that under normal conditions suppresses forming of a tumor and orders the cells containing a defective DNA to 'commit suicide' by apoptosis.

Sabotaging treatment: who is behind that?

A SMO protein suppression, enabled by a medicine called Vismodegib, neutralizes breach's consequences in a chain interaction controlled by the Sonic hedgehog gene. Thanks to that medicine, the orders of the commander do not reach its subjects, and the job of the whole chain is stopped: so, pulling one of the first dominoes in a row, you can prevent falling of all other.

Though in 50% of cases the tumor tissue either does not react to medical treatment, or develop resistance. It is SMO protein mutations responsible for a half of those complications: they prevent interaction of Vismodegib and SMO, however reasons for the second half remain unknown.

That is why scientists payed attention to the fact that 85% of basal carcinoma contain genetic mutations, related to other cancer types development, including far more dangerous, such as melanoma.

After detecting those oncogenic gene mutations, scientists managed to confirm activation of corresponding cancer tracts experimentally. One of the important observations made during the research was that the detected mutations are often seen in a subtype of aggressive basaliomas.

'We researched the peculiarities of mutation process happening in basalis cellular carcinoma cells. More than 100 of cancer exomes (a part of genome consisting of protein-coding DNA sequences) allow both to find out, which genes provoke this type of cancer, and to research, which processes help storing mutations (most of which do not influence cancer development even in cancer samples). We compared mutation profile of basal cell carcinoma with other cancer type -- melanoma, also provoked by ultraviolet radiation. As the result we managed conclude that oxidative stress and UV play a more important role in basal cell carcinoma development,' tells Vladimir Seplyarskiy.

Criminogenic schemes

To catch the remaining accomplices red-handed in that nearly detective story, biologists analyzed 293 species of tumor tissues of 236 patients. 30 species belonged to Gorlin syndrome sufferers (a genetic disease, dramatically increasing the likelihood of multiple basaliomas appearance). Among them were also 23 Vismodegib-resistiant and 259 not exposed to the medicine.

Scientists compared mutations in basalioma, melanoma, Wilson disease (kidney cancer usually formed in the first-third year of life) and other cancer types, which are probably connected with Sonic hedgehog gene and its 'accomplices' of the same pathway.

The inquiry showed: of 387 genes in the 'list of suspects' several may contribute to the appearance of basalis cellular carcinoma and developing sustainability to treatment. Among them -- genes forming Hippo-YAP pathway, and not only Sonic hedgehog controlled pathways, that used to bear the whole responsibility. Also in basal carcinoma N-Myc protein content were exceeded, that was caused by point mutation (replacement of one nucleotide - a DNA 'letter') in ??1 site. In other tumor types, where N-Myc protein in a high concentration was 'caught red-handed' earlier, the reason was a mutation provoking multiple increase of MYCN gene's copies.

According to Vladimir Seplyarskiy, 'this study is a turning point in understanding molecular mechanisms of appearance and development of basalis carcinoma. The fact that basilioma cells are subject to oxidative stress may give start to an alternative anticancer therapy of basalis cellular carcinoma.'. The results also show which mutagens affect DNA damage in skin cells, the researcher says.
-end-


Lomonosov Moscow State University

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".